	US 12,227,758 B2
	Somatic haploid human cell line
Tilmann Buerckstuemmer, Vienna (AT)
Assigned to HORIZON DISCOVERY LIMITED, Cambridge (GB)
Filed by HORIZON DISCOVERY LIMITED, Cambridge (GB)
Filed on Sep. 11, 2019, as Appl. No. 16/567,087.
Application 16/567,087 is a continuation of application No. 15/100,146, granted, now 10,450,586, previously published as PCT/EP2014/076029, filed on Nov. 28, 2014.
Claims priority of application No. 13194939 (EP), filed on Nov. 28, 2013; application No. 13194940 (EP), filed on Nov. 28, 2013; application No. PCT/EP2014/066732 (WO), filed on Aug. 4, 2014; application No. 14181367 (EP), filed on Aug. 19, 2014; and application No. 14191914 (EP), filed on Nov. 5, 2014.
Prior Publication US 2020/0032294 A1, Jan. 30, 2020
Int. Cl. C12N 15/90 (2006.01); C12N 5/071 (2010.01); C12Q 1/6813 (2018.01)

CPC C12N 15/907 (2013.01) [C12N 5/0602 (2013.01); C12N 15/902 (2013.01); C12Q 1/6813 (2013.01); C12N 2800/30 (2013.01)]

10 Claims

1. A method of producing a somatic karyotypically stable fully haploid human cell line, comprising:

a) providing a somatic near-haploid human parental cell, wherein the somatic near-haploid human parental cell does not comprise more than 5 chromosomes in two or more copies;

b) identifying a disomic chromosomal region in a genome of the parental cell;

c) deleting the identified disomic chromosomal region using a CRISPR/Cas9 system to obtain a fully haploid cell, wherein the deleted chromosomal region has a length of at least 1 million bp; and

d) expanding the fully haploid cell to obtain the somatic karyotypically stable fully haploid human cell line.